{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:02:49Z","timestamp":1773298969484,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T00:00:00Z","timestamp":1307491200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bioidentical Hormone Replacement Therapy (BHRT) is believed it to be a safer and equally effective alternative to Conventional Hormone Therapy for the relief of menopausal symptoms; however, data are needed to support these claims. The objective of this study is to evaluate the effectiveness of compounded BHRT provided in six community pharmacies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was an observational cohort study of women between the ages of 18-89 who received a compounded BHRT product from January 1, 2003 to April 30, 2010 in six community pharmacies. Data included patient demographics, comorbidities, therapeutic outcomes, and hormone therapies. Women self-rated menopausal symptoms as absent, mild, moderate, or severe. Descriptive statistics were used to characterize the patient population, BHRT use, and adverse events. Patient symptom severity was compared at baseline and 3 to 6 months follow-up using the Wilcoxon signed-rank test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Women (n = 296) receiving BHRT at Oakdell Pharmacy had a mean (standard deviation) age of 52 (9) years. The most common BHRT dosage forms utilized were topical (71%) and oral (43%). Compounded BHRT regimens were generally initiated at low doses regardless of route. Women experienced a 25% decrease in emotional lability (p &lt; 0.01), a 25% decrease in irritability (p &lt; 0.01), and a 22% reduction in anxiety (p = 0.01) within 3 to 6 months. These women also experienced a 14% reduction in night sweats (p = 0.09) and a 6% reduction in hot flashes (p = 0.50).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study demonstrates that compounded BHRT improves mood symptoms. Larger studies are needed to examine the impact on vasomotor symptoms, myocardial infarction and breast cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6874-11-27","type":"journal-article","created":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T06:35:31Z","timestamp":1307601331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effectiveness of Compounded Bioidentical Hormone Replacement Therapy: An Observational Cohort Study"],"prefix":"10.1186","volume":"11","author":[{"given":"Andres D","family":"Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly R","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie C","family":"Barner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R","family":"Frei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,8]]},"reference":[{"key":"241_CR1","volume-title":"Personal Communication. Professional Compounding Centers of America","author":"B Biundo","year":"2008","unstructured":"Biundo B: Personal Communication. Professional Compounding Centers of America. 2008, San Antonio"},{"key":"241_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3810\/pgm.2009.01.1949","volume":"121","author":"K Holtorf","year":"2009","unstructured":"Holtorf K: The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?. Postgrad Med. 2009, 121: 73-85.","journal-title":"Postgrad Med"},{"key":"241_CR3","first-page":"336","volume":"5","author":"J Lorentzen","year":"2001","unstructured":"Lorentzen J: Hormone replacement therapy: The evolution of hormone treatment. Int J Pharmaceut Compounding. 2001, 5: 336.","journal-title":"Int J Pharmaceut Compounding"},{"key":"241_CR4","first-page":"10","volume":"5","author":"S Wepfer","year":"2001","unstructured":"Wepfer S: The science behind bioidentical hormone replacement therapy. Int J Pharmaceut Compounding. 2001, 5: 10.","journal-title":"Int J Pharmaceut Compounding"},{"key":"241_CR5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/01.AOG.0000284450.51264.31","volume":"110","author":"GA Bachmann","year":"2007","unstructured":"Bachmann GA, Schaefers M, Uddin A, Utian WH: Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007, 110: 771-9. 10.1097\/01.AOG.0000284450.51264.31.","journal-title":"Obstet Gynecol"},{"key":"241_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archpsyc.58.6.529","volume":"58","author":"CN Soares","year":"2001","unstructured":"Soares CN, Almeida OP, Joffe H, Cohen LS: Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001, 58: 529-34. 10.1001\/archpsyc.58.6.529.","journal-title":"Arch Gen Psychiatry"},{"key":"241_CR7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/humrep\/15.5.1028","volume":"15","author":"K Takahashi","year":"2000","unstructured":"Takahashi K, Okada M, Ozaki T, et al: Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod. 2000, 15: 1028-36. 10.1093\/humrep\/15.5.1028.","journal-title":"Hum Reprod"},{"key":"241_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/01.AOG.0000254160.62588.41","volume":"109","author":"JA Simon","year":"2007","unstructured":"Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC: Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007, 109: 588-96. 10.1097\/01.AOG.0000254160.62588.41.","journal-title":"Obstet Gynecol"},{"key":"241_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S0029-7844(99)00643-2","volume":"95","author":"M Notelovitz","year":"2000","unstructured":"Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J: Initial 17 beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000, 95: 726-31. 10.1016\/S0029-7844(99)00643-2.","journal-title":"Obstet Gynecol"},{"key":"241_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1471-0528.1986.tb08034.x","volume":"93","author":"ML Padwick","year":"1986","unstructured":"Padwick ML, Siddle NC, Lane G, et al: Oestriol with oestradiol verses oestradiol alone: a comparison of endometrial, symptomatic and psychological effects. Br J Obstet Gynaecol. 1986, 93: 606-12. 10.1111\/j.1471-0528.1986.tb08034.x.","journal-title":"Br J Obstet Gynaecol"},{"key":"241_CR11","doi-asserted-by":"crossref","unstructured":"Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010, 17: 242-55. 10.1097\/gme.0b013e3181d0f6b9.","DOI":"10.1097\/gme.0b013e3181d0f6b9"},{"key":"241_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0029-7844(99)00266-5","volume":"94","author":"HB Leonetti","year":"1999","unstructured":"Leonetti HB, Longo S, Anasti JN: Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol. 1999, 94: 225-8. 10.1016\/S0029-7844(99)00266-5.","journal-title":"Obstet Gynecol"},{"key":"241_CR13","first-page":"13","volume":"10","author":"BG Wren","year":"2003","unstructured":"Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA: Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause. 2003, 10: 13-8.","journal-title":"Menopause"},{"key":"241_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1258\/mi.2009.009014","volume":"15","author":"B Benster","year":"2009","unstructured":"Benster B, Carey A, Wadsworth F, Vashisht A, Domoney C, Studd J: A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause Int. 2009, 15: 63-9. 10.1258\/mi.2009.009014.","journal-title":"Menopause Int"},{"key":"241_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/09513590500128583","volume":"21","author":"A Vashisht","year":"2005","unstructured":"Vashisht A, Wadsworth F, Carey A, Carey B, Studd J: A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. Gynecol Endocrinol. 2005, 21: 101-5. 10.1080\/09513590500128583.","journal-title":"Gynecol Endocrinol"},{"key":"241_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-33. 10.1001\/jama.288.3.321.","journal-title":"JAMA"},{"key":"241_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/jama.280.7.605","volume":"280","author":"S Hulley","year":"1998","unstructured":"Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. JAMA. 1998, 280: 605-13. 10.1001\/jama.280.7.605.","journal-title":"JAMA"},{"key":"241_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jama.1995.03520270033028","volume":"273","author":"Effects of estrogen or estrogen\/progestin regimens on heart disease risk factors in postmenopausal women","year":"1995","unstructured":"Effects of estrogen or estrogen\/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen\/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995, 273: 199-208.","journal-title":"JAMA"},{"key":"241_CR19","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1161\/01.CIR.98.12.1158","volume":"98","author":"M Gerhard","year":"1998","unstructured":"Gerhard M, Walsh BW, Tawakol A, et al: Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 1998, 98: 1158-63.","journal-title":"Circulation"},{"key":"241_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.7326\/0003-4819-135-11-200112040-00005","volume":"135","author":"HN Hodis","year":"2001","unstructured":"Hodis HN, Mack WJ, Lobo RA, et al: Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001, 135: 939-53.","journal-title":"Ann Intern Med"},{"key":"241_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0015-0282(16)57482-2","volume":"63","author":"KJ Chang","year":"1995","unstructured":"Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignieres B: Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995, 63: 785-91.","journal-title":"Fertil Steril"},{"key":"241_CR22","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0015-0282(98)00042-9","volume":"69","author":"JM Foidart","year":"1998","unstructured":"Foidart JM, Colin C, Denoo X, et al: Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril. 1998, 69: 963-9. 10.1016\/S0015-0282(98)00042-9.","journal-title":"Fertil Steril"},{"key":"241_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","volume":"107","author":"A Fournier","year":"2008","unstructured":"Fournier A, Berrino F, Clavel-Chapelon F: Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008, 107: 103-11.","journal-title":"Breast Cancer Res Treat"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-11-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6874-11-27\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-11-27","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-11-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T14:18:59Z","timestamp":1630505939000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/1472-6874-11-27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,8]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["241"],"URL":"https:\/\/doi.org\/10.1186\/1472-6874-11-27","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,8]]},"assertion":[{"value":"29 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"27"}}